CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 83 enrolled
Drug / intervention
Estradiol +2 moredrug
Likely dose
Estradiol 2.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04192266
NCT04192266Phase 3Completed

A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy

The University of Texas Health Science Center, Houston·interventional·Posted Dec 10, 2019·Updated Jan 9, 2026

In Brief

A Phase 3 clinical trial evaluating Estradiol, Placebo oral tablet, and 1 other intervention for PTSD. Completed, enrolled 83 participants across 2 sites.

Detailed Summary

The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Houston and UPenn (40 subjects at each site). Participants will be randomized into one of two groups, PE + E2 or PE + placebo. The study will include preliminary screening and baseline visits, experimental visits, and therapy visits over the course of six weeks. Several follow-up visits will take place.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesUnited States

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedDec 10, 2019
Enrollment StartJun 24, 2020
Primary CompletionMay 29, 2024
Study CompletionDec 2, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.6 years ago

Interventions

Estradioldrug

2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)

Placebo oral tabletdrug

2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)

Prolonged Exposure (PE) therapybehavioral

There will be an introductory Prolonged Exposure (PE) therapy session, followed by 5 imaginal exposure sessions, such that there will be 2 sessions per week conducted for a total of 6 sessions over 3 weeks. The PE sessions are 60 minutes long and consist of imaginal exposure. Specifically, the patient is instructed to imagine the trauma and recount it aloud for about 25-30 minutes. In the following 15 minutes, the patient processes her reactions to revisiting the traumatic event by discussing related thoughts and feelings. The session ends with in vivo exposure homework to be completed that same day as the session. In the last session, imaginal exposure is conducted one last time for the same duration as previous sessions. The therapist and patient review treatment progress and discuss applications of treatment principles to daily life.